Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2CNS 2Thoracic 1Sarcoma 1Plasma cell 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Cyclophosphamide 54Specimen Handling 50Magnetic Resonance Spectroscopy 49pembrolizumab 43Doxorubicin 43Radiotherapy 42Temozolomide 37Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Surgical Procedures, Operative 19Ifosfamide 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12Etoposide 12Blood Specimen Collection 12Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
efineptakin alfa × Sarcoma × 1 year × Clear all
NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Mayo Clinic

Phase 2 Recruiting
54 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡